RetinalGenix Technologies Inc. (RTGN) Form 10-Q — May 20, 2026
RetinalGenix Technologies reported a net loss of $590,489 for the quarter ended March 31, 2026, with cash reserves depleted to just $180. The company disclosed substantial doubt about its ability to continue as a going concern, stating it lacks adequate resources to fund operations beyond June 2026 without additional capital. The filing reveals a material weakness in internal controls over financial reporting due to a lack of segregation of duties, a significant governance risk for investors. Additionally, the company’s CFO, M.
Key figures
- Revenue
- 0
- Total Debt
- 2563889
- Cash Position
- 180
- Shares Outstanding
- 18843628
- Due to sanovas
- 830632
- Offering price
- 2.25
- Total liabilities
- 2563889
- Rd expense q1 2025
- 13214
- Rd expense q1 2026
- 117064
- Accumulated deficit
- 18449106
- Gna expense q1 2026
- 262149
- Shares sold may 2026
- 88888
- Stock based compensation q1 2026
- 210016
- Subsequent equity raise may 2026
- 200000
Price after filing
Close on the filing date to close N calendar days later (from $4.00). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.